Examination of Setarud (IMOD™) in the management of patients with severe sepsis by Mahmoodpoor, A. et al.
Examination of Setarud (IMOD™) in the management of patients with 
severe sepsis
1Mahmoodpoor A., 2Eslami K., 1,2Mojtahedzadeh M., 1Najafi A., 1Ahmadi A., 1Dehnadi-Moghadam 
A., 2Mohammadirad A., 2Baeeri M., *2Abdollahi M.
1Department of Critical Care Medicine, Sina Hospital, School of Medicine, 2Faculty of Pharmacy, 
and  Pharmaceutical  Sciences  Research  Center,  Tehran  University  of  Medical  Sciences, 
Tehran, Iran.
Received 4 Oct 2009; Revised 28 Dec 2009; Accepted 12 Jan 2010 
ABSTRACT
Background and the purpose of the study: Analysis of current immunomodulating strategies 
indicates that monovalent approaches are unlikely to restore immunostasis or achieve complete 
therapy of sepsis. Setarud (IMOD) as a mixture of urtica, carotenoids, urea, and selenium has 
been recently patented for its potential in reduction of Tumor Necrosis Factor alpha (TNF-α) 
and Interferon-γ and Interleukin-2 levels. The aim of this study was to examine efficacy of 
IMOD in the management of patients with severe sepsis.
Methods: Twenty patients with severe sepsis and acute physiology and chronic health evaluation 
(APACHE) score of more than 20 were randomized to receive standard treatment of severe 
sepsis (control group) or standard treatment plus IMOD (IMOD group). The group treated with 
IMOD for 14 days was according to the pilot study and regarding the stability of patient’s 
conditions in the ICU. Of course patients in both groups received standard treatment and all 
were monitored for 28 days. Blood samples were analyzed for interleukins (IL-1, IL-2, IL-6), 
plasminogen activator inhibitor (PAI-1), TNF-α, total thiol molecules (TTM), nitric oxide (NO), 
total antioxidant power (TAP), and lipid peroxidation (LPO). Daily APACHE, Sequential Organ 
Failure Assessment (SOFA), and Simplified Acute Physiology Score (SAPS) were calculated.
Results and major conclusion: Comparing with controls, IMOD was significantly effective in 
improving SAPS, SOFA, and APACHE scores, and reduction of mortality rate. Among tested 
inflammatory biomarkers, IMOD significantly improved TTM and TNF-α values. 
It is concluded that IMOD might be added as a safe adjutant to standard treatment of severe sepsis. 
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INTRODUCTION
Sepsis  is  among  the  most  common  reasons  for 
admission to intensive care units throughout the world 
and it represents a major burden to health care system. 
Regarding the complexities of sepsis, all aspects of 
body  inflammatory  response  should  be  targeted  to 
achieve better management of patients (1,2).
Following the initial host and microbial interaction, 
inflammatory  cytokines  are  released  by  activated 
macrophages  and  CD4  cells  within  the  first  hour 
after  infection.  Proinflammatory  mediators  are 
counteracted  by  antiinflammatory  molecules  such 
as IL-4, IL-10, and IL1-ra because CD4 T cells can 
switch from the production of inflammatory cytokines 
to  production  of  antiinflammatory  cytokines  (3). 
Immunotherapy  must  be  applied  at  an  early  time 
point during the development of immunodysfunction 
following trauma or acute onset of infection to ensure 
that all cellular components of immune system are 
protected. There is much earlier temporal relationship 
between  inflammation  and  the  onset  of  organ 
dysfunction.  Mean  biomarker  levels  during  72  hrs 
were significantly greater in hospital non-survivors. 
Therefore, inflammatory elements such as TNF-α and 
IL-1 should be therapeutically targeted and neutralized 
(4). In early severe sepsis and septic shock, within the 
first 3 hrs of hospital presentation, distinct biomarker 
patterns  emerge  in  response  to  hemodynamic 
optimization strategies (5). A significant association 
exists between temporal biomarker patterns in the first 
72 hrs, severity of tissue hypoxia, organ dysfunction, 
and the mortality (6).
Analysis  of  current  immunomodulating  strategies 
indicates  that  monovalent  approaches  in  isolation 
are  unlikely  to  restore  immunostasis  or  attain 
status of complete therapy. It is likely that multiple 
immunomodulating  strategies  will  be  necessary  to 
achieve clinical success owing to complex interplay 
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recommended severe sepsis bundles were implemented 
as follow: 
Severe sepsis resuscitation bundle, which began 
immediately not later than 6 hrs after diagnose of severe 
sepsis. The bundle contained serum lactate measure-
ment, blood cultures before antibiotic administration, 
improving time to broad spectrum antibiotics, control 
of hypotension by vasopressors to target central venous 
pressure, and central venous oxygen saturation. The 
second  bundle  called  sepsis  management  bundle 
began not later than 24 hrs after diagnosis of severe 
sepsis. The protocol contained administration of low 
dose of steroids, adequate glycemic control, and 
prevention of excessive inspiratory plateau pressure.
Patients in IMOD group received 125 mg (4 ml) of 
IMOD in 100 ml of DW5% which was infused over 
1 hour on the first day. All hemodynamic data were 
noted during the infusion in order to stop it  in the 
case of any negative hemodynamic deterioration, 
dermal rash, urticaria and anaphylactic reaction. Then 
8 ml of IMOD in 100 ml of DW5% was infused 
everyday up to 14 days. The time gap between the 
beginning of treatment with IMOD and the diagnosis 
of sepsis was also noted to evaluate possible impact 
of the onset time of IMOD on mortality. 
Demographic  data  and  clinical  information  were 
obtained  at  the  beginning  (Table  1).  Daily  acute 
physiology and chronic health evaluation (APACHE), 
sequential  organ  failure  assessment  (SOFA),  and 
simplified  acute  physiology  score  (SAPS)  were 
calculated  (4,11).  Higher  scores  indicate  more 
severe  illness  and  a  higher  number  of  therapeutic 
interventions.
Death  from  any  causes  during  intensive  care,  the 
number of days in the ICU, the need for mechanical 
ventilatory assist, renal replacement therapy, inotropic 
or  vasopressor  support,  blood  infection,  and 
transfusion requirements were recorded. Of course 
after  a  14-day  protocol,  the  standard  treatment  of 
sepsis was continued during patients stay in the ICU. 
Mortality during ICU stay and mortality during 28 
days were also noted.
Sample collection and handling
All patients had central venous catheters and arterial 
line for blood sampling. For all patients there were 
seven  scheduled  time  points  for  determination  of 
IL-1,  IL-2,  IL-6,  plasminogen  activator  inhibitor 
(PAI-1), TNF-α, total thiol molecules (TTM), nitric 
oxide (NO), total antioxidant power (TAP), and lipid 
peroxidation (LPO) by the standard methods as 
described previously (12). The first sample was taken 
on ICU admission and before initiation of treatment. 
Other samples were obtained on days of 1, 2, 3, 7, 10, 
and 14 after starting  of therapy. Blood samples were 
collected  into  vacutainer  tubes  containing  EDTA. 
The samples were then centrifuged at 3000×g for 15 
minutes, and the plasma was separated and stored at 
-80°C until analysis. 
between  pathways.  Botanical  extracts  provides 
cytoprotective,  antiinflammatory,  and  antimicrobial 
activities in addition to immunoregulatory activity (7).
Setarud (IMOD) is a mixture of urtica, carotenoids, 
urea,  and  selenium  that  can  regulate  TNF-α, 
interferone-γ  (IFN-γ)  and  IL-2.  IMOD  has  been 
patented in Europe with code of WO/2007/087825 
for its immunomodulator and anti-TNF-α capacities 
and  improving  CD4  in  HIV  positive  patients 
(8).  The  pre-clinical  safety  studies  of  IMOD  in 
animals, and phases I trials have been successfully 
conducted  showing  optimistic  results  (9,10).  As 
sepsis is an immune mediated disease and IMOD 
has immunomodulatory properties, in this study its 
effect in management of patients with severe sepsis 
was evaluated.          
METHODS
Subjects
Patients  with  severe  sepsis  and  APACHE  (Acute 
Physiology And Chronic Health Evaluation) score of 
more than 20 who admitted to general ICU of Sina 
Hospital of Tehran University of Medical Sciences 
were enrolled in this study.
Exclusion criteria were any of the following: age less 
than 18 years old, pregnancy, lactating women, organ 
transplant history, and death probability within 24 hrs.
Treatment protocol
This study was a randomized open labeled clinical trial 
that was approved by TUMS review board and registered 
at Australian Newzeland Clinical Trial Organisation 
with  code  number  of  (ACTRN012607000376448). 
Twenty patients with severe sepsis and APACHE score 
of more than 20 were enrolled in this trial. Patients were 
randomized to receive one of the following treatments: 
standard treatment for severe sepsis (control group) 
and standard treatment plus IMOD (IMOD group) for 
duration of 14 days. The group treated for 14 day with 
IMOD was selected according to the results of pilot 
studies and regarding the stability of patient’s conditions 
in the ICU. Of course patients in both group received 
standard treatment and all were monitored for 28 days. 
According  to  last  international  guidelines,  two 
Control Group IMOD Group
Age (year) 52.20±14.42 37.60±20.26
Male/Female 50% 37.60%
APACHE II 27.60±7.21 30.40±4.57
SAPS 53.60±4.34 45.00±7.48
SOFA 7.80±4.52 7.00±5.12
Table 1. Demographic and baseline characteristic of patients.
Data are mean±SD. APACHE: Acute Physiologic And Chronic 
Health Evaluation. SAPS: Simplified Acute Physiologic Score. 
SOFA: Sequential Organ Failure Assessment.25 Setarud (IMOD™) in the management of severe sepsis
Statistical analyses
The  statistical  analysis  was  performed  using 
StatsDirect  2.6.6  software.  Results  were  expressed 
as  mean±SE.  Because  of  small  sample  size  and 
probability  of  abnormal  distribution  of  data,  the 
nonparametric  test  for  comparison  of  intra  and 
inter groups was used. Variations within groups (in 
comparison to baseline) were evaluated by Wilcoxon 
W  test.  Differences  between  two  protocols  were 
assessed  by  Mann Whitney  test.  P-value less than 
0.05 was considered statistically significant.
RESULTS
Twenty  patients  with  severe  sepsis  and  APACHE 
score of more than 20 were included in this study. Two 
patients in IMOD group were excluded, one patient 
had  positive  lab  results  for  HIV  and  another  one 
needed amputation because of thrombotic gangrene 
of lower limb but he refused undergoing amputation.
Demographic  and  baseline  values  for  APACHE, 
SAPS, and SOFA are presented in table 1. The source 
of sepsis and results of biological cultures are shown 
in table 2. The changes in biomarker values and mortal-
ity  and  morbidity  during  the  study  are  shown  in 
figures 1-12. Comparing with controls, IMOD was 
significantly  effective  in  improving  SAPS,  SOFA, 
and APACHE  scores. Among  tested  inflammatory 
biomarkers, IMOD significantly improved TTM and 
TNF-α. The changes of remaining biomarkers including 
IL-1, IL-2, IL-6, TAP, LPO, NO, and PAI were not 
different between groups.
In  IMOD  group,  the  mortality  rate  was  40% 
during  28  days  while  it  was  50%  in  controls 
(P<0.05).
DISCUSSION
Despite great advancement in understanding of 
the  pathophysiology  and  development  of  novel 
therapeutic approaches, mortality of sepsis remains 
unacceptably high (13). As mentioned earlier, the key 
point of severe sepsis is immune dysfunction 
suggesting that therapies should overcome immune 
dysfunction to improve clinical outcome. Several studies 
evaluated the effect of different treatments on severe 
sepsis, but failed to improve survival of patients 
for  many  different explanations. For example the 
experimental agents have been ineffective or the 
dose of experimental agents have been inadequate 
(14) or the timing of intervention has not been suitable 
(15, 16). In addition, there has been polymorphism 
(17) or heterogeneity (18) in patients under study. The 
treatment of sepsis is currently limited to activated 
protein C and moderate doses of corticosteroids. 
Activated protein C is associated with increased risk 
of hemorrhage that limits its use in patients with high 
risk of bleeding. High cost of activated protein C is 
another limitation. Previous studies have shown that 
monovalent therapies by itself could not restore 
immunostasis in severe sepsis (19), so the need to 
drugs  with  polyvalent  activity  like  botanical 
immunodrugs  seems  inevitable  (7).  Botanical 
immunodrugs  such  as  Chinese  remedy  and  green 
tea have been found that dose-dependently attenuate 
bacterial  endotoxin-induced  HMGBI  release  (20). 
IMOD  is  a  new  herbal-derived  remedy  which  has 
been already tested for toxicity in animals and found 
safe (11). 
Results  of  this  study  indicated  that  TNF-α  as  the 
main  inflammatory  mediator  of  severe  sepsis  was 
reduced  by  IMOD  treatment  in  comparison  to 
controls. One of the outcomes of reduction in TNF-α 
would  be  the  decline  in  many  deleterious  effects 
including inflammation, apoptosis, and cytotoxicity. 
Interestingly,  it  was  found  a  significant  elevation 
in TTM by IMOD during the treatment (Figure 9). 
Glutathione  is  the  major  low  molecular  weight 
thiol in the mammalian and it constitutes the most 
important  antioxidant  defense,  thus  measurement 
of  TTM,  allowed  to  monitor  glutathione  action. 
Although, positive effects of IMOD was not found 
on  all  biomarkers  of  inflammation  or  toxic  stress 
but  APACHEE,  SOFA,  and  SAPS  as  quantitative 
indices of clinical status were improved by IMOD 
and  mortality  rate  at  the  day  of  28  was  reduced. 
Improvement of APACHEE, SOFA, and SAPS by 
IMOD confirms potential of IMOD in alleviation of 
severity of disease and dynamics. 
Fortunately,  IMOD  showed  no  adverse  effect  on 
coagulation factors like platelet count, prothrombine 
time,  partial  thromboplastin  time,  fibrinogen,  and 
D-dimer. Hemodynamic instability and anaphylactoid 
reactions were not observed during infusion that is 
very important in septic patients who are vulnerable 
to little hemodynamic changes. Two patients in IMOD 
group  had  immune  mediated  thrombocytopenia 
which improved after treatment. In one patient under 
treatment  with  IMOD,  a  significant  improvement 
in PaO2/FiO2 ratio was observed. Dose of 125 mg 
Source of infection Abdomen Lung Urinary tract Central nervous system
Number of cases 3 5 3 3
Detected organism Acinetobacter P. Aeroginosa S. Aerus Klebsiella C. Albicans
Number of cases 3 5 2 5 1
Table 2. Source of infection and detected organisms of patients26 Mahmoodpoor et al / DARU 2010 18 (1) 23 - 28
Figure 1. Changes in bood NO levels in different days of study.
Data  are  mean±SE.  Difference  between  two  groups  is  not 
significant (P>0.05).
Figure 2. Changes in blood TNF-α level in different days of study.
Data are mean±SE. **Difference between two groups is significant 
at P<0.01. 
Figure 3. Changes in blood IL-1 levels in different days of study.
Data  are  mean±SE.  Difference  between  two  groups  is  not 
significant (P>0.05).
Figure 4. Changes in blood IL-2 levels in different days of study.
Data are mean±SE. Difference between two groups is not significant 
(P>0.05).
Figure 5. Changes in blood IL-6 levels in different days of study.
Data are mean±SE. Difference between two groups is not significant 
(P>0.05).
Figure 6. Changes in blood TAP in different days of study.
Data are mean±SE. Difference between two groups is not significant 
(P>0.05).
Figure 7. Changes in blood LPO in different days of study.
Data are mean±SE. Difference between two groups is not significant 
(P>0.05).
Figure 8. Changes in blood tPAI in different days of study.
Data are mean±SE. Difference between two groups is not significant 
(P>0.05).
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for IMOD that was used in the present study is in 
the safe dose range and much less than toxic doses 
(10) and thus can be increased in future trials. One 
of limitations of the present study is small sample 
size but as a matter of fact it is difficult to have large 
sample size in ICU with critically ill patients because 
of heterogeneity of patients. In addition, a new study 
demonstrated that most of studies in ICU have the 
same limitations and endpoints other than mortality 
need to be considered when evaluating interventions 
in critically ill patients. It has been concluded that 
relatively  few  of  the  randomized  controlled  trials 
conducted  in  ICU  show  beneficial  impact  of  the 
intervention on the survival (21).
Figure 9. Changes in blood TTM in different days of study.
Data are mean±SE. ** Difference between two groups is significant 
at P<0.01. 
Figure 10. Changes of patients SOFA in different days of study.
Data are mean±SE. ** Difference between two groups is significant 
at P<0.01.
Taking collectively, it is concluded that that IMOD 
may be added as a safe adjuvant to standard treatment 
of  severe  sepsis.  This  is  the  first  study  showing 
safety profile and possible antiinflammatory effect of 
IMOD in sepsis which might be extrapolated to acute 
respiratory syndrome and shock too. Further clinical 
trials  with  larger  sample  size  and  higher  doses  of 
IMOD are necessary to show exact antiinflammatory 
and immunomodulatory effects of IMOD in patients 
with septic shock.
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